U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C24H31N3O2S
Molecular Weight 425.587
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CARPHENAZINE

SMILES

CCC(=O)C1=CC=C2SC3=CC=CC=C3N(CCCN4CCN(CCO)CC4)C2=C1

InChI

InChIKey=XZSMZRXAEFNJCU-UHFFFAOYSA-N
InChI=1S/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://edudrugs.com/P/Proketazine/more.html | https://en.wikipedia.org/wiki/Carfenazine | https://www.ncbi.nlm.nih.gov/pubmed/14267601

Carfenazine (brand name Proketazine) is an antipsychotic and tranquilizer of the phenothiazine group. It is used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients. Proketazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. The following is a list of possible side effects that may occur from all constituting ingredients of Proketazine: akathisia, tardive dyskinesia, extrapyramidal symptoms, allergic purpura.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PROKETAZINE

Approved Use

Used in the treatment of acute or chronic schizophrenic reactions in hospitalized patients.
Doses

Doses

DosePopulationAdverse events​
100 mg 4 times / day steady, oral
Dose: 100 mg, 4 times / day
Route: oral
Route: steady
Dose: 100 mg, 4 times / day
Sources:
unhealthy, 18 - 60 years
Health Status: unhealthy
Age Group: 18 - 60 years
Sex: F
Sources:
Disc. AE: Skin rash...
Other AEs: Faintness...
AEs leading to
discontinuation/dose reduction:
Skin rash (grade 4, 1 patient)
Other AEs:
Faintness (1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Faintness 1 patient
100 mg 4 times / day steady, oral
Dose: 100 mg, 4 times / day
Route: oral
Route: steady
Dose: 100 mg, 4 times / day
Sources:
unhealthy, 18 - 60 years
Health Status: unhealthy
Age Group: 18 - 60 years
Sex: F
Sources:
Skin rash grade 4, 1 patient
Disc. AE
100 mg 4 times / day steady, oral
Dose: 100 mg, 4 times / day
Route: oral
Route: steady
Dose: 100 mg, 4 times / day
Sources:
unhealthy, 18 - 60 years
Health Status: unhealthy
Age Group: 18 - 60 years
Sex: F
Sources:
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

First week, 25 mg. t.i.d.; second week, 50 mg. t.i.d.; third week, 75 mg. t.i.d.; fourth week, 100 mg. t.i.d.; fifth week and thereafter, 100 mg. q.i.d.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
CARFENAZINE
INN   WHO-DD  
INN  
Preferred Name English
CARPHENAZINE
MI  
Common Name English
CARPHENAZINE [MI]
Common Name English
carfenazine [INN]
Common Name English
Carfenazine [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29710
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
Code System Code Type Description
CAS
2622-30-2
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
DRUG CENTRAL
516
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
DRUG BANK
DB01038
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
NCI_THESAURUS
C73285
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
MERCK INDEX
m1057
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY Merck Index
ECHA (EC/EINECS)
220-072-9
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
FDA UNII
CLY16Y8Z7E
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
CHEBI
51235
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
WIKIPEDIA
Carfenazine
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
ChEMBL
CHEMBL1201328
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
IUPHAR
7140
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
EPA CompTox
DTXSID8022745
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
INN
1179
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
PUBCHEM
18104
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
SMS_ID
100000084572
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY
EVMPD
SUB06625MIG
Created by admin on Wed Apr 02 08:26:08 GMT 2025 , Edited by admin on Wed Apr 02 08:26:08 GMT 2025
PRIMARY